Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid TumorsToshio Shimizu, Anthony W. Tolcher, Lon Smith et al.|Clinical Cancer Research|2014Cited by 82
Antiobesity effect of L-arabinose via ameliorating insulin resistance and modulating gut microbiota in obese miceXiang‐Fei Li, Zifan Cai, Jie Liu et al.|Nutrition|2023Cited by 21
RETRACTED: Mir-124 Attenuates STAT3-Mediated TH17 Differentiation in Colitis-Driven Colon CancerShiyong Lin, Jing Wang|Frontiers in Oncology|2020Cited by 11